Introduction
Over the last half-century, the emergence and evolution of critical care has made possible the conduct of incredibly complex lifesaving surgery and the recovery of untold thousands of critically ill medical patients who previously had no chance of survival [1] . Despite this success, most interventions delivered to critically ill patients were adopted based on physiological theory or "borrowed" from other settings, e.g., positive pressure ventilation from the operating room and fluid resuscitation from the infirmaries and battlefields of the world wars. While this approach was entirely appropriate in the early days of our specialty, it is now clear that many standard practices of the past, and some new ones, harmed the very patients they were designed to help. We know this predominantly because academic researchers have designed and conducted high-quality, robust, pragmatic randomised clinical trials (RCTs); many of the trials that have improved the care of our patients have reported neutral or negative treatment effects.
Clinical trials in critical care
The conduct of RCTs in critical care is challenging; patients are rarely able to give or withhold consent, diagnosis may be unclear early in the clinical course, making complex inclusion criteria difficult to apply, interventions are often time-critical, and the natural trajectory of critical illness is incredibly variable. Although clinical trial methodology is continually evolving with exciting new methods such as adaptive and platform trials being brought to bear [2, 3] , most high-quality evidence comes from traditional individual or cluster RCTs, which, simplistically, can be divided into efficacy and effectiveness trials [4] . Efficacy trials are designed to answer the question, "Does this intervention work in the ideal patient population in the ideal circumstances?" Efficacy trials typically use complex inclusion and exclusion criteria and are the appropriate design when investigating the likely impact of a new intervention [4] . Efficacy trials sacrifice the ability to apply their results to real-world practice in pursuit of maximal internal validity. In contrast, effectiveness trials, also called pragmatic trials, are designed to determine the effect of an intervention when it is used in more a diverse population or typical clinical settings [5] . Notable features include simplified inclusion and exclusion criteria that seek to maximise generalisability and thus to understand the true impact of new and established treatments on outcomes important to patients [5] .
The impact of trials that demonstrate harm
On this background it is both rational and essential to test as many of the interventions used in critical care as possible. Priority should be given to interventions that are used for to many patients, interventions that are costly or labour intensive and those for which there is insufficient evidence to reliably estimate the balance between benefit and harm. That the risk of us causing harm to our patients is real is confirmed by a recent systematic review that reported on RCTs in critical care in which the intervention studied significantly affected mortality; mortality was increased by half the interventions studied 
Trial

Result
Practice change/benefit TRICC [11] In general ICU patients with anaemia, the use of a lower vs. higher Hb-threshold for transfusion did not affect 30-day mortality Reduced blood transfusion in ICU patients reduces stress on transfusion services
Low-dose dopamine [12] In ICU patients with SIRS and early renal dysfunction, the use of dopamine vs. placebo did not affect renal dysfunction
Use of dopamine may be stopped in general ICU patients if not beneficial as later studies showed use of dopamine was associated with increased adverse effects SAFE [13] In general ICU patients, the use of albumin vs. saline did not affect mortality or any other outcomes The use of albumin may be stopped in general ICU patients, saving scarce resources RENAL [14] In ICU patients with AKI, higher vs. lower intensity CRRT did not reduce mortality at 90 days
The use of higher intensity CRRT may be stopped in ICU patients-significant economic benefits PROWESS SHOCK [15] In ICU patients with persistent septic shock, the use of APC vs. placebo did not affect mortality or any other outcome APC removed from market, reducing risk of haemorrhagic complication and saving money TRISS [16] In ICU patients with septic shock and anaemia, the use of a lower vs. higher Hb threshold for transfusion did not affect mortality or any other outcome Less blood may be used in patients with septic shock reducing stress on transfusion services ABLE [17] TRANSFUSE [18] In ICU patients with anaemia, fresher vs. standard issued or older blood did not affect mortality The use of fresher blood may be stopped in ICU patients, reducing stress on transfusion services PRISM [19] In patients with septic shock in the emergency department, early goal-directed therapy vs. usual care did not affect mortality or any other outcome Early goal-directed therapy may be stopped in patients with septic shock-economic benefits and avoidance of potentially harmful protocolised interventions TTM [20] In unconscious adult survivors of out-of-hospital cardiac arrest targeted temperature management at 33 °C versus 36 °C did not improve mortality or neurological recovery
Cooling to 33 °C is unnecessary meaning less intense therapy, use of less sedation and making earlier neurological prognostication possible [6] . Notably critical trials that report harm are generally of higher quality, being more likely to be multi-centred and blinded and have larger sample sizes [7] . Importantly, many interventions shown to be harmful in highquality trials were in regular clinical use at the time of testing, including high-frequency oscillatory ventilation [8] , hydroxyethyl starch [9] and intensive glucose control [10] . In reaction to these results, clinicians, guideline writers and regulators have taken actions to reduce the use of harmful interventions and thus to improve outcomes for our patients.
The impact of trials that report a neutral treatment effect
A positive, a neutral and a negative result for a given test of intervention X vs. intervention Y will be highly informative for clinicians, those writing clinical practice guidelines and policy-makers and healthcare funders provided the research is of high quality and free from significant risk of bias. The results of robust pragmatic trials allow everyone to change clinical practice with confidence. Some of the many RCTs with neutral results that have allowed us to provide better and more cost-effective care are listed in Table 1 .
Simplifying critical care
Trials reporting neutral or negative treatment effects are important in the process of simplifying critical care as they show us what not to do. As many standard critical care interventions and therapeutic targets are being challenged, simplifying care becomes increasingly rational from the patient, organisational and financial perspective. Doing less may improve patients' outcomes, reduce the number of drug interactions and adverse events and save money. Doing less allows us to focus our efforts on what is important to patients, notably to reduce pain, anxiety, thirst, breathlessness and other distressing symptoms. Additionally, simplification will harmonise care, which will facilitate staff training. Simple care will form a cleaner baseline for observational and interventional research and thereby increase the likelihood of developing new diagnostics, risk scores and interventions that will be useful for future patients.
Summary
While it is tempting to be disappointed when an RCT reports that a new or established treatment does not have demonstrable beneficial effects, or even harms our patients, such information is critical and has undoubtedly contributed to the improved outcomes now experienced by critically ill patients. We must stop characterising such results as "negative trials" and instead celebrate the knowledge they provide and encourage all critical care practitioners to incorporate that knowledge into their decision making at the bedside.
